Plamotamab (XmAb-13676) is a human bispecific antibody designed to target CD3 and CD20 simultaneously. This antibody facilitates the recruitment of cytotoxic T cells to CD20-expressing tumor cells, promoting targeted cell-mediated cytotoxicity. In vivo studies have demonstrated that Plamotamab effectively induces tumor regression. Additionally, it is associated with a mild hematologic reaction, highlighting its potential therapeutic benefits with manageable side effects. This product is pivotal for research focused on innovative cancer immunotherapies, particularly in the context of hematologic malignancies.
Plamotamab (XmAb-13676) is a human bispecific antibody designed to target CD3 and CD20 simultaneously. This antibody facilitates the recruitment of cytotoxic T cells to CD20-expressing tumor cells, promoting targeted cell-mediated cytotoxicity. In vivo studies have demonstrated that Plamotamab effectively induces tumor regression. Additionally, it is associated with a mild hematologic reaction, highlighting its potential therapeutic benefits with manageable side effects. This product is pivotal for research focused on innovative cancer immunotherapies, particularly in the context of hematologic malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
